|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2011-5-30
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Pemetrexed has emerged as one of the most active agents for the treatment of patients with advanced non-small cell lung cancer (NSCLC). We conducted a phase II study to assess the efficacy and feasibility of integrating pemetrexed in a concurrent therapy plan for patients with stage III NSCLC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/ERCC1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Endonucleases,
http://linkedlifedata.com/resource/pubmed/chemical/Glutamates,
http://linkedlifedata.com/resource/pubmed/chemical/Guanine,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/Thymidylate Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel,
http://linkedlifedata.com/resource/pubmed/chemical/pemetrexed
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1556-1380
|
|
pubmed:author |
pubmed-author:BelzerKimberlyK,
pubmed-author:BurgerAngelika MAM,
pubmed-author:ChenWeiW,
pubmed-author:GadgeelShirish MSM,
pubmed-author:HackstockDeborahD,
pubmed-author:KonskiAndreA,
pubmed-author:MarquetteLaurenL,
pubmed-author:PatelBhaumik BBB,
pubmed-author:RuckdeschelJohn CJC,
pubmed-author:TurrisiAndrewA,
pubmed-author:ValdiviesoManuelM,
pubmed-author:WozniakAntoinetteA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
927-33
|
|
pubmed:meshHeading |
pubmed-meshheading:21415776-Adenocarcinoma,
pubmed-meshheading:21415776-Adult,
pubmed-meshheading:21415776-Aged,
pubmed-meshheading:21415776-Aged, 80 and over,
pubmed-meshheading:21415776-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21415776-Carcinoma, Large Cell,
pubmed-meshheading:21415776-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:21415776-Carcinoma, Squamous Cell,
pubmed-meshheading:21415776-Cisplatin,
pubmed-meshheading:21415776-Combined Modality Therapy,
pubmed-meshheading:21415776-DNA-Binding Proteins,
pubmed-meshheading:21415776-Endonucleases,
pubmed-meshheading:21415776-Feasibility Studies,
pubmed-meshheading:21415776-Female,
pubmed-meshheading:21415776-Follow-Up Studies,
pubmed-meshheading:21415776-Glutamates,
pubmed-meshheading:21415776-Guanine,
pubmed-meshheading:21415776-Humans,
pubmed-meshheading:21415776-Lung Neoplasms,
pubmed-meshheading:21415776-Male,
pubmed-meshheading:21415776-Middle Aged,
pubmed-meshheading:21415776-Neoplasm Recurrence, Local,
pubmed-meshheading:21415776-Neoplasm Staging,
pubmed-meshheading:21415776-Survival Rate,
pubmed-meshheading:21415776-Taxoids,
pubmed-meshheading:21415776-Thymidylate Synthase,
pubmed-meshheading:21415776-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
|
|
pubmed:affiliation |
Thoracic Oncology Program, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan, USA. gadgeels@karmanos.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
